Stifel Nicolaus Reaffirms Their Buy Rating on HEALWELL AI (AIDX)

In a report released on November 3, Justin Keywood from Stifel Nicolaus maintained a Buy rating on HEALWELL AI, with a price target of C$3.80.

Meet Your ETF AI Analyst

• Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
• Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Keywood is an analyst with an average return of -6.1% and a 44.38% success rate. Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, DRI Healthcare, and HEALWELL AI.

In addition to Stifel Nicolaus, HEALWELL AI also received a Buy from Maxim Group’s Allen Klee in a report issued on November 4. However, on October 31, TR | OpenAI – 4o reiterated a Hold rating on HEALWELL AI (TSX: AIDX).

Based on HEALWELL AI’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of C$40.52 million and a GAAP net loss of C$4.18 million. In comparison, last year the company earned a revenue of C$5.44 million and had a net profit of C$2.58 million

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AIDX in relation to earlier this year.